McBane Robert D, Wysokinski Waldemar E
Division of Cardiovascular Medicine, Mayo Clinic and Foundation for Education and Research, 200 Southwest First Street, Rochester, MN 55905, USA.
Curr Treat Options Cardiovasc Med. 2008 Apr;10(2):136-45. doi: 10.1007/s11936-008-0015-z.
The literature is filled with randomized controlled trial data to guide most steps in managing patients with deep venous thrombosis of the extremities or pulmonary embolism. Venous thrombosis, however, is not limited to these locations and may involve the cerebral venous sinuses, renal veins, splanchnic veins, and ovarian veins. The causes of these thrombi are often unique to the venous segments involved and typically stem from pathologies of the organs supplied by these veins. Very little randomized controlled trial data exist to guide therapy for these atypical venous thrombi. Treatment should focus on correcting the underlying disease and relieving venous congestion of the involved organ while preserving organ functionality. Although natural history data are limited, recurrence rates for these atypical venous thrombi appear to be relatively low. Indefinite secondary anticoagulant prophylaxis is therefore primarily dictated by the congenital or acquired pathology precipitating the event.
文献中充斥着随机对照试验数据,以指导四肢深静脉血栓形成或肺栓塞患者管理的大多数步骤。然而,静脉血栓形成并不局限于这些部位,可能累及脑静脉窦、肾静脉、内脏静脉和卵巢静脉。这些血栓的病因通常因所累及的静脉段而异,通常源于这些静脉所供应器官的病变。几乎没有随机对照试验数据可用于指导这些非典型静脉血栓的治疗。治疗应侧重于纠正潜在疾病,缓解受累器官的静脉充血,同时保留器官功能。尽管自然史数据有限,但这些非典型静脉血栓的复发率似乎相对较低。因此,长期二级抗凝预防主要取决于引发该事件的先天性或后天性病变。